Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16233604 | 0.90 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2AKDM4EPKM | |
| SCHEMBL24955577 | 0.86 | KDM4E (0.36) | ALDH1A1MEN1KMT2AKDM4EPKM | |
| SCHEMBL16233648 | 0.84 | MEN1 (0.34) | ALDH1A1MEN1KMT2AKDM4EPKM | |
| SCHEMBL21289837 | 0.82 | MEN1 (0.36) | ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13347183 | 0.81 | KDM4E (0.34) | ALDH1A1KDM4EPKM | |
| SCHEMBL997725 | 0.80 | MEN1 (0.33) | ALDH1A1MEN1KMT2APKM | |
| SCHEMBL16770070 | 0.77 | KDM4E (0.36) | KDM4EPKM | |
| SCHEMBL13604640 | 0.74 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL4572169 | 0.74 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL18198076 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025097104-A1 | THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| WO-2024080788-A1 | NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF | 한미약품 주식회사 | 2024-04-18 | — | — | WO | disclosed |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-7268141-B2 | Xanthine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268141-B2 | Xanthine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2007-09-11 | — | — | US | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
| US-20070129346-A1 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2007-06-07 | — | — | US | disclosed |
| US-20070037831-A1 | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-20070037831-A1 | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| EP-1228070-B1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037831-A1 | Methods of using PDE 5 inhibitors for the treatment of congestive heart failure | PDE5A, PDE3A, PDE3B | ALDH1A1 814/4885MEN1 4450/4885KMT2A 2992/4885 |
| US-20070129346-A1 | Melanocortin receptor agonists | MC1R, MC3R, MC5R | ALDH1A1 1226/4885MEN1 632/4885KMT2A 1824/4885 |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | ALDH1A1 2922/4885MEN1 3/4885KMT2A 198/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885MEN1 2085/4885KMT2A 73/4885 |
| US-20070149562-A1 | OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | MC5R, MC4R, OPRD1 | ALDH1A1 338/4885MEN1 1662/4885KMT2A 2511/4885 |
| US-12030870-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK2, JAK1, JAK3 | ALDH1A1 1300/4885MEN1 3192/4885KMT2A 640/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | ALDH1A1 633/4885MEN1 1383/4885KMT2A 2234/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | ALDH1A1 3400/4885MEN1 1685/4885KMT2A 1132/4885 |
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 1300/4885MEN1 3192/4885KMT2A 640/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | ALDH1A1 2429/4885MEN1 791/4885KMT2A 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.